CGRP mAb Iv denied as non-formulary by Humana?

Humana's specific coverage criteria for cgrp mab iv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Your IV CGRP Monoclonal Antibody — Non-Formulary

Humana's formulary (drug list) may not include the specific intravenous CGRP monoclonal antibody your physician prescribed, or may list it at a tier that effectively makes it unaffordable. A "non-formulary" denial does not mean the drug is not covered for anyone — it means your current plan tier does not include it by default. You have two parallel paths: a formulary exception request (which runs through the same appeal process) and, separately, a review of whether a formulary-listed CGRP agent could meet your clinical needs.

## Why This Denial Is Appealable

Under ACA §2719 and most state regulations, plans must have a process for formulary exceptions when a non-formulary drug is medically necessary because all formulary alternatives are contraindicated, have been tried and failed, or are otherwise clinically inappropriate for a specific patient. If your prescriber can document that the formulary alternatives are not suitable for you, a formulary exception appeal has strong grounds.

## Federal Appeal Framework

• Formulary exception request: This is the primary path. File simultaneously with or immediately following your initial denial. Humana must have a documented exception process.
• Internal appeal: If the exception request is denied, file a formal internal appeal under ACA §2719 / ERISA §503 within the deadline on the denial letter.
• External review: If upheld internally, escalate to independent external review within approximately four months of the final internal denial.
• Expedited review: Available for urgent situations; document current clinical burden.

## Documentation to Gather

1. Humana formulary — download your current plan's drug formulary and identify (a) whether any CGRP mAb is on-formulary and at what tier, and (b) whether the IV formulation specifically is excluded or merely placed at a high tier. 2. Trial-and-failure records for formulary alternatives — if a formulary-listed CGRP agent was tried and failed, document: drug name, dates of use, and chart-documented outcome. 3. Clinical rationale for the specific agent — prescriber letter explaining why the non-formulary drug is necessary versus any formulary alternative, with clinical reasoning (not just preference). 4. Diagnosis and prior-treatment summary — chart notes documenting diagnosis and the full preventive treatment history. 5. Formulary exception criteria — obtain from Humana the published criteria for granting a formulary exception; map your documentation to each criterion.

## Criteria-Mapping Structure

| Formulary Exception Criterion | Supporting Evidence | |---|---| | Formulary alternative tried and failed | [Drug name, dates, chart-documented outcome] | | Formulary alternative contraindicated or inappropriate | [Prescriber letter, clinical rationale, date] | | Non-formulary drug is medically necessary | [Prescriber letter mapping to Humana criteria] | | Diagnosis confirmed | [Chart note, date, provider] |